News | April 18, 2021
Lonza and Immunitas announce manufacturing agreement
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
The IPO comprises a fresh issue of up to Rs. 11,600 million and an offer for sale of up to 7,305,245 equity shares of Rs. 2 each of Glenmark Life Sciences by Glenmark Pharmaceuticals
Acquisition of A&C expands Aceto’s Western manufacturing footprint
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
Sapropterin dihydrochloride powder for oral solution is available in 100 mg unit dose
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
Subscribe To Our Newsletter & Stay Updated
